The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students

Exclusion Criteria

• •History of mumps or have completed 3 doses of mumps-containing vaccine;
• •Receipt of the current seasonal influenza vaccine (except subjects in Arm 4)
• •History of asthma or allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;
• •Congenital malformations or developmental disorders, genetic defects, severe malnutrition;
• •Autoimmune disease (such as systemic lupus erythematosus) or a state of immunodeficiency / immunosuppression (such as AIDS, after organ transplantation);
• •Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;
• •Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
• •Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, any condition resulting in asplenia or splenectomy;
• •Abnormal coagulation function diagnosed by a doctor (such as coagulation factor deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder;
• •Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, topical corticosteroid therapy for acute uncomplicated dermatitis) within the past 6 months;
• •Receipt of blood products in the past 3 months;
• •Receipt of other investigational drugs in the past 30 days;
• •Receipt of attenuated live vaccines in the past 28 days;
• •Receipt of inactivated or subunit vaccines in the past 7 days;
• •Onset of various acute or chronic diseases within 7 days prior to the study;
• •Axillary temperature \>37.0°C;
• •Participation in other clinical trials before enrollment and during the follow-up period, or a plan to participate in other clinical trials within 3 months.
• •Any other factors that are unsuitable for participating in this clinical trial according to the investigator's judgment